ChirayuGCCChirayuGCC
    All posts
    Pharma
    Hyderabad
    Life Sciences
    Biotechnology
    Medical Devices
    Semiconductors
    Clinical Research
    GCC
    Strategy

    The Definitive Guide to Setting Up Pharmaceutical, Life Sciences and Semiconductor Global Capability Centres (GCCs) in Hyderabad, India in 2026-2027

    A pillar guide for global Chief Executive Officers (CEOs), Chief Scientific Officers (CSOs), Chief Medical Officers (CMOs), Chief Technology Officers (CTOs) and Heads of Global Capability Centres (GCCs) planning a Pharmaceutical, Life Sciences, Biotechnology, Medical Devices, Clinical Research and Semiconductor Global Capability Centre (GCC) in Hyderabad and the Genome Valley, HITEC City, Gachibowli, Nanakramguda, Pocharam and Adibatla corridors.

    TL;DR

    A pillar guide for global Chief Executive Officers (CEOs), Chief Scientific Officers (CSOs), Chief Medical Officers (CMOs), Chief Technology Officers (CTOs) and Heads of Global Capability Centres (GCCs) planning a Pharmaceutical, Life Sciences, Biotechnology, Medical Devices, Clinical Research and Semiconductor Global Capability Centre (GCC) in Hyderabad and the Genome Valley, HITEC City, Gachibowli, Nanakramguda, Pocharam and Adibatla corridors.

    25 June 2026Hyderabad, India37 min readBy ChirayuGCC Research Team
    Quick Enquiry, get a tailored GCC plan in 1 business day
    EnquireWhatsAppCall

    Jai Shri Krishna. Hyderabad is the global capital of the Indian Pharmaceutical and Life Sciences Global Capability Centre (GCC) market and a rising global capital of the Indian semiconductor Global Capability Centre (GCC) market. This pillar guide is the most comprehensive public document on building a Pharmaceutical, Life Sciences, Biotechnology, Medical Devices, Clinical Research, Healthcare Information Technology (IT) or Semiconductor Global Capability Centre (GCC) in Hyderabad.

    1. Executive Summary, the One Page You Can Walk Into a Board Meeting With

    • Hyderabad hosts approximately 350 Global Capability Centres (GCCs) employing more than 280,000 professionals, of which approximately 95,000 are in Pharmaceutical, Life Sciences, Biotechnology, Medical Devices and Clinical Research roles.
    • Hyderabad produces approximately one third of the world's vaccine doses by volume and is home to Bharat Biotech, Biological E, Indian Immunologicals, Shantha Biotechnics (Sanofi), Hetero, Aurobindo, Dr Reddy's Laboratories, Divi's Laboratories, Granules India, Laurus Labs, Suven and the Indian Pharmaceutical and Life Sciences Global Capability Centres (GCCs) of Novartis, Sanofi, Bristol Myers Squibb, GlaxoSmithKline (GSK), Pfizer, Bayer, Merck KGaA, Eli Lilly, AstraZeneca, Roche, Takeda, Boehringer Ingelheim, Bayer Crop Science and Syngenta.
    • Genome Valley is the largest contiguous Life Sciences cluster in India with 200 plus companies, 50 plus Research and Development (R&D) institutions, 14 million plus square feet of Life Sciences ready Grade A and laboratory space and a dedicated Biosafety Level 3 (BSL 3) infrastructure.
    • Hyderabad is the second largest semiconductor design cluster in India after Bangalore and is closing the gap rapidly. Anchor employers include Qualcomm, Advanced Micro Devices (AMD), Microsoft Silicon, Intel, Nokia, Cirrus Logic, NXP, MediaTek and Western Digital. The Telangana State Semiconductor Policy and the India Semiconductor Mission have positioned Hyderabad as the second pole of the India semiconductor design corridor.
    • Fully loaded cost arbitrage for a mid level Hyderabad Life Sciences scientist, clinical researcher or semiconductor engineer versus an equivalent in New Jersey, Boston, Basel, Cambridge United Kingdom (UK), San Diego or Tel Aviv is 65 per cent to 78 per cent.
    • Real estate cost in HITEC City, Gachibowli and Nanakramguda is INR 75 to INR 105 per square foot per month, 18 per cent to 25 per cent cheaper than Outer Ring Road (ORR) Bangalore.
    • Attrition in Hyderabad Pharmaceutical and Life Sciences Global Capability Centres (GCCs) is 13 per cent to 17 per cent, materially below the Bangalore technology range and on par with Pune.
    • The Telangana Industrial Policy and the dedicated Hyderabad Pharma City (15,000 acres at Mucherla) provide structural infrastructure, single window approvals and Common Effluent Treatment Plant (CETP) capacity unavailable in any other Indian city.
    • Hyderabad Rajiv Gandhi International Airport is the cleanest, fastest and most globally connected Indian airport with daily long haul connectivity to North America, Europe, the Middle East and South East Asia.
    • A 400 Full-Time Equivalent (FTE) Pharmaceutical and Life Sciences Global Capability Centre (GCC) in Hyderabad can be productive within 10 to 13 months of board approval under a Build-Operate-Transfer (BOT) structure with an Integrated Partner like ChirayuGCC.

    2. Why Hyderabad, Specifically for Pharmaceutical, Life Sciences and Semiconductors

    2.1 The vaccine and biologics thesis

    Hyderabad produces approximately one third of the world's vaccine doses by volume. The combination of Bharat Biotech, Biological E, Indian Immunologicals, Shantha Biotechnics (Sanofi) and Bharat Serums and Vaccines anchors a manufacturing and Research and Development (R&D) cluster that no other Indian city, and few global cities, can match. The companion Research and Development (R&D) infrastructure, including the Centre for DNA Fingerprinting and Diagnostics (CDFD), the Centre for Cellular and Molecular Biology (CCMB), the Indian Institute of Chemical Technology (IICT), the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad and the University of Hyderabad, produces an annual talent pipeline that is unmatched in India for biologics, vaccines, cell and gene therapy and small molecule discovery.

    2.2 The talent thesis

    Hyderabad produces approximately 18,000 fresh Life Sciences and Biotechnology graduates per year, approximately 4,500 fresh Master of Pharmacy (MPharm) and Doctor of Pharmacy (PharmD) graduates, approximately 6,000 fresh Master of Science (MSc) Chemistry graduates and approximately 2,200 fresh PhD holders in Chemistry, Biology and Pharmaceutical sciences. The lateral pool exceeds 95,000 Pharmaceutical and Life Sciences professionals. For semiconductors, Hyderabad produces approximately 35,000 engineering graduates per year and hosts a lateral pool of more than 45,000 semiconductor and embedded engineers.

    2.3 The Genome Valley thesis

    Genome Valley, anchored at Shameerpet, is the largest contiguous Life Sciences cluster in India with 200 plus companies, dedicated Biosafety Level 3 (BSL 3) laboratories, animal facilities, central instrumentation, vivarium support and shared scale up infrastructure. For a global Pharmaceutical and Life Sciences Global Capability Centre (GCC) that needs wet laboratory adjacency in addition to a Knowledge Process Outsourcing (KPO) charter, Genome Valley is unique in the Indian Global Capability Centre (GCC) landscape.

    2.4 The Hyderabad Pharma City thesis

    Hyderabad Pharma City at Mucherla, the world's largest integrated cluster for Pharmaceutical manufacturing and Research and Development (R&D), spans 15,000 acres with dedicated Common Effluent Treatment Plant (CETP) capacity, Zero Liquid Discharge (ZLD) infrastructure, a Pharma University and dedicated residential and social infrastructure. For Pharmaceutical Global Capability Centres (GCCs) that pair Research and Development (R&D), regulatory, supply chain and manufacturing analytics with a downstream Indian Active Pharmaceutical Ingredient (API) or formulation manufacturing presence, Hyderabad Pharma City is a structural advantage.

    2.5 The semiconductor thesis

    Hyderabad has become the second pole of the India semiconductor design corridor. Qualcomm, Advanced Micro Devices (AMD), Microsoft Silicon, Intel, Nokia, Cirrus Logic, NXP, MediaTek and Western Digital run major design centres in Hyderabad. The Telangana State Semiconductor Policy provides dedicated land, power and water guarantees for semiconductor design and Outsourced Semiconductor Assembly and Test (OSAT) units. For a global semiconductor parent that wants a second India site after Bangalore, Hyderabad is now the default answer.

    3. The Hyderabad Micro-Market Map, Where to Locate the Global Capability Centre (GCC)

    • HITEC City, Hyderabad Information Technology Engineering Consultancy City, 25 million plus square feet of Grade A stock. Anchor tenants include Microsoft, Google, Amazon, Meta, Apple India, Wells Fargo, JPMorgan Chase, Bank of America, Goldman Sachs, Deloitte, Accenture, Cognizant, Tata Consultancy Services (TCS), Infosys, Wipro, Capgemini, ServiceNow, Salesforce, Oracle, SAP Labs, IBM and the Indian Global Capability Centres (GCCs) of Novartis, Sanofi, Bristol Myers Squibb, GlaxoSmithKline (GSK), Pfizer, Bayer, Roche, Takeda and Boehringer Ingelheim. Rent INR 80 to INR 105 per square foot per month.
    • Gachibowli Financial District, 12 million plus square feet of Grade A stock. Anchor tenants include the Indian Global Capability Centres (GCCs) of Microsoft, Amazon Web Services (AWS), Franklin Templeton, Bank of America, UBS, BNY Mellon, Deutsche Bank, Wells Fargo and DBS. Rent INR 85 to INR 110 per square foot per month.
    • Nanakramguda Information Technology (IT) Corridor, 8 million plus square feet of Grade A stock. Anchor tenants include the Indian Global Capability Centres (GCCs) of Bank of America, Wells Fargo, BNY Mellon, Hexagon, Cyient and several mid market parents. Rent INR 75 to INR 95 per square foot per month.
    • Genome Valley, Shameerpet, 14 million plus square feet of Life Sciences ready laboratory and office space. Anchor tenants include Bharat Biotech, Biological E, Shantha Biotechnics, Novartis Knowledge Centre, GlaxoSmithKline Research and Development (GSK R&D), Aurobindo Pharma, Dr Reddy's Laboratories, Divi's Laboratories, Suven Life Sciences, Bharat Serums and Vaccines, Indian Immunologicals and the Centre for DNA Fingerprinting and Diagnostics (CDFD). Rent INR 55 to INR 85 per square foot per month for office, with separately tendered laboratory and Biosafety Level 3 (BSL 3) infrastructure.
    • Pocharam Information Technology Investment Region (ITIR), 6 million plus square feet of Grade A stock. Anchor tenants include the Indian Global Capability Centres (GCCs) of Infosys, Tata Consultancy Services (TCS), Wipro, Genpact and several mid market parents. Rent INR 55 to INR 75 per square foot per month.
    • Adibatla aerospace and defence cluster, 5 million plus square feet of Grade A stock plus dedicated aerospace and defence manufacturing land. Anchor tenants include Tata Boeing Aerospace, Tata Sikorsky, Tata Advanced Systems, Adani Aerospace, GMR Aerospace Park, Cyient Defence, Safran and Pratt and Whitney. Rent INR 60 to INR 85 per square foot per month.

    4. The Pharmaceutical and Life Sciences Global Capability Centre (GCC) Charter, What Hyderabad Owns

    4.1 Research and Development (R&D), discovery and translational science

    • Target identification, target validation, hit identification, hit to lead and lead optimisation
    • Medicinal chemistry, computational chemistry, structure based drug design, machine learning aided drug discovery
    • In vitro pharmacology, in vivo pharmacology, Absorption Distribution Metabolism Excretion Toxicology (ADMET)
    • Biologics discovery, antibody engineering, bispecifics, antibody drug conjugates, gene therapy, cell therapy
    • Bioinformatics, computational biology, omics analytics, single cell sequencing analytics, multi omics integration
    • Real World Evidence (RWE), Real World Data (RWD), epidemiology, health economics and outcomes research (HEOR)

    4.2 Clinical operations, clinical data and clinical research

    • Clinical trial protocol design, statistical analysis plan, case report form design
    • Clinical site monitoring, site management, patient recruitment analytics
    • Clinical data management, Electronic Data Capture (EDC), database lock, data review
    • Biostatistics, statistical programming, Statistical Analysis System (SAS) and R programming, CDISC SDTM, ADaM, define.xml
    • Medical writing, clinical study reports, integrated summaries, regulatory submission writing
    • Pharmacovigilance, individual case safety reports (ICSRs), periodic safety update reports (PSURs), signal detection, risk management plans

    4.3 Regulatory affairs and quality

    • United States of America (USA) Food and Drug Administration (FDA) submissions: Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Biologics License Application (BLA)
    • European Medicines Agency (EMA) submissions: Marketing Authorisation Application (MAA), Centralised Procedure, Mutual Recognition Procedure
    • Pharmaceuticals and Medical Devices Agency (PMDA) Japan, China National Medical Products Administration (NMPA), India Central Drugs Standard Control Organisation (CDSCO) submissions
    • Common Technical Document (CTD) authoring, electronic Common Technical Document (eCTD) publishing
    • Quality Management System (QMS), Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP)
    • Computer System Validation (CSV), Computer Software Assurance (CSA) under the United States of America (USA) Food and Drug Administration (FDA) 2024 guidance

    4.4 Commercial, medical affairs and Health Economics and Outcomes Research (HEOR)

    • Medical Science Liaison (MSL) support, Key Opinion Leader (KOL) engagement support, publication planning
    • Medical Information (MI) call centre and Medical Information (MI) content authoring
    • Health Economics and Outcomes Research (HEOR), payer evidence generation, value dossiers
    • Market access, pricing analytics, reimbursement analytics
    • Promotional review, Medical Legal Regulatory (MLR) review support

    4.5 Healthcare Information Technology (IT) and digital health

    • Electronic Health Record (EHR) interoperability, Fast Healthcare Interoperability Resources (FHIR) integration
    • Clinical Decision Support (CDS) systems, Artificial Intelligence (AI) for radiology, pathology and oncology
    • Software as a Medical Device (SaMD) development under the International Medical Device Regulators Forum (IMDRF)
    • Digital therapeutics (DTx), connected devices, remote patient monitoring
    • Healthcare Insurance Portability and Accountability Act (HIPAA), 21 Code of Federal Regulations (CFR) Part 11, European Union (EU) Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), Digital Personal Data Protection (DPDP) Act 2023 readiness

    4.6 Semiconductors (parallel charter in HITEC City and Gachibowli)

    • Register Transfer Level (RTL) design, Application Specific Integrated Circuit (ASIC) and System on Chip (SoC) design
    • Verification, formal verification, Universal Verification Methodology (UVM), emulation, simulation
    • Physical design, place and route, signoff
    • Analog, mixed signal, Radio Frequency (RF), Power Management Integrated Circuit (PMIC)
    • Embedded software, firmware, device drivers, Real Time Operating System (RTOS)
    • Outsourced Semiconductor Assembly and Test (OSAT) operations support

    5. Compensation Bands for Hyderabad Pharmaceutical, Life Sciences and Semiconductor Global Capability Centres (GCCs) in 2026

    • Entry level (0 to 2 years) Life Sciences Associate (MSc or BPharm), fully loaded annual cost: INR 7 lakh to INR 12 lakh
    • Mid level (3 to 6 years) Scientist or Senior Associate (MPharm, PhD), fully loaded annual cost: INR 14 lakh to INR 28 lakh
    • Senior Scientist or Principal Scientist (PhD, 7 to 12 years), fully loaded annual cost: INR 28 lakh to INR 55 lakh
    • Director, Research and Development (R&D) or Clinical, fully loaded annual cost: INR 60 lakh to INR 1.4 crore
    • Vice President (VP), Research and Development (R&D) or Clinical or Regulatory, fully loaded annual cost: INR 1.4 crore to INR 3.2 crore
    • Biostatistician, mid level, fully loaded annual cost: INR 18 lakh to INR 40 lakh
    • Statistical Programmer (Statistical Analysis System (SAS), R), mid level, fully loaded annual cost: INR 16 lakh to INR 36 lakh
    • Regulatory Affairs Specialist, mid level, fully loaded annual cost: INR 18 lakh to INR 38 lakh
    • Pharmacovigilance Scientist, mid level, fully loaded annual cost: INR 14 lakh to INR 30 lakh
    • Semiconductor Verification Engineer, mid level, fully loaded annual cost: INR 30 lakh to INR 65 lakh
    • Semiconductor Physical Design Engineer, senior, fully loaded annual cost: INR 55 lakh to INR 1.4 crore
    • Country Head, Hyderabad Pharmaceutical and Life Sciences Global Capability Centre (GCC), fully loaded annual cost: INR 3.5 crore to INR 7.5 crore
    • Equivalent fully loaded costs in New Jersey, Boston, Basel, Cambridge United Kingdom (UK) or San Diego: 3.5 to 5.0 times the Hyderabad number

    6. The Technology Stack for a 2026 Hyderabad Pharmaceutical and Life Sciences Global Capability Centre (GCC)

    • Electronic Lab Notebook (ELN) and Laboratory Information Management System (LIMS): Benchling, Dotmatics, IDBS E-WorkBook, LabWare, STARLIMS
    • Clinical: Veeva Vault Clinical, Medidata Rave, Oracle Clinical, IBM Clinical Development, Calyx, Signant Health
    • Regulatory: Veeva Vault RIM, IQVIA Regulatory, Lorenz docuBridge, Extedo eCTDmanager
    • Quality and Document Management: Veeva Vault Quality, MasterControl, Sparta TrackWise, Pilgrim
    • Pharmacovigilance: Oracle Argus Safety, ArisGlobal LifeSphere, Veeva Vault Safety
    • Statistical: Statistical Analysis System (SAS), R, Python, Posit (RStudio), Stata
    • Bioinformatics: Geneious, CLC Workbench, DNAnexus, Seven Bridges, Lifebit, Nextflow, Snakemake
    • Artificial Intelligence (AI) and Machine Learning (ML): NVIDIA Clara, Microsoft Azure Health Data Services, AWS HealthLake, Google Cloud Healthcare API, Atomwise, BenevolentAI, Insilico Medicine, Owkin platforms
    • Enterprise Resource Planning (ERP) and Supply Chain: SAP S/4HANA Life Sciences, Oracle Fusion, Kinaxis, o9, Blue Yonder
    • Semiconductor Electronic Design Automation (EDA): Synopsys, Cadence, Siemens EDA (Mentor), Ansys, Keysight

    7. Operating Model, Captive Versus Build-Operate-Transfer (BOT) Versus Managed

    7.1 Direct captive

    Direct captive in Hyderabad is the right model for global Pharmaceutical and Life Sciences parents with USD 5 billion plus in revenue. Time to a productive 200 Full-Time Equivalent (FTE) unit, 11 to 14 months.

    7.2 Build-Operate-Transfer (BOT)

    Build-Operate-Transfer (BOT) in Hyderabad with an Integrated Partner like ChirayuGCC is the right model for mid market Pharmaceutical, Biotechnology and Medical Devices parents with USD 500 million to USD 5 billion in revenue. Time to a productive 100 Full-Time Equivalent (FTE) unit, 5 to 7 months.

    7.3 Managed Global Capability Centre (GCC)

    Managed Global Capability Centre (GCC) is the right model for emerging Biotechnology and Medical Devices parents that want a dedicated Hyderabad team but do not want an Indian legal entity.

    8. The 30, 60, 90 Day Launch Plan for a Hyderabad Pharmaceutical and Life Sciences Global Capability Centre (GCC)

    • Day 0 to Day 30, board approval, charter sign off, Hyderabad micro market selection (HITEC City and Gachibowli for Knowledge Process Outsourcing (KPO), Genome Valley for wet laboratory adjacency, Pharma City for manufacturing adjacency), partner selection, three shortlisted buildings
    • Day 30 to Day 60, incorporation, tax registrations (Permanent Account Number (PAN), Tax Deduction and Collection Account Number (TAN), Goods and Services Tax (GST), Software Technology Parks of India (STPI), Department of Biotechnology (DBT) and Telangana State Industrial Infrastructure Corporation (TSIIC) where applicable), bank account, lease signature, fit-out kick off, hiring of the first 10 leadership roles including the Country Head, the Head of Research and Development (R&D), the Head of Clinical, the Head of Regulatory, the Head of Quality and the Head of Information Technology (IT)
    • Day 60 to Day 90, fit-out completion, technology stack go live, hiring of the first 40 to 60 Full-Time Equivalents (FTEs), parent knowledge transfer, first molecule, protocol, submission or programme go live by day 90

    9. Transfer Pricing, Intellectual Property (IP) and the Total Cost Model

    The standard structure for a Hyderabad Pharmaceutical and Life Sciences Global Capability Centre (GCC) is a cost plus mark up under the Central Board of Direct Taxes (CBDT) safe harbour at 18 per cent for Knowledge Process Outsourcing (KPO) work. For high value Research and Development (R&D), discovery and translational work, a benchmarked Transfer Net Margin Method (TNMM) with an Advance Pricing Agreement (APA) under Section 92CC of the Income Tax Act, 1961, provides nine year tax certainty. Intellectual Property (IP) ownership defaults to the parent under standard work for hire and assignment language, with careful drafting under the Indian Patents Act 1970, the Indian Biological Diversity Act 2002 and the Nagoya Protocol where applicable. The Department of Biotechnology (DBT), the Department of Scientific and Industrial Research (DSIR) and the Telangana Department of Industries and Commerce provide additional incentives including Research and Development (R&D) weighted deduction under Section 35(2AB) of the Income Tax Act, 1961.

    10. Risk, Controls and Audit Defence

    • United States of America (USA) Food and Drug Administration (FDA) 21 Code of Federal Regulations (CFR) Parts 11, 210, 211, 314, 600, 820
    • European Medicines Agency (EMA) Good Practice (GxP) guidelines, EudraLex Volume 4
    • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) E6 (R3), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) Q7 to Q14, Pharmacovigilance E2A to E2F
    • International Medical Device Regulators Forum (IMDRF) Software as a Medical Device (SaMD) guidelines
    • International Standards Organisation (ISO) 13485 for Medical Devices, ISO 14971 for Medical Device Risk Management, ISO 27001 for Information Security
    • Health Insurance Portability and Accountability Act (HIPAA), General Data Protection Regulation (GDPR), Digital Personal Data Protection (DPDP) Act 2023, Indian Biological Diversity Act 2002, Nagoya Protocol
    • United States of America (USA) Food and Drug Administration (FDA) Computer Software Assurance (CSA) 2024 guidance, Computer System Validation (CSV)
    • Anti Bribery and Anti Corruption (ABAC) under the Foreign Corrupt Practices Act (FCPA), Pharmaceutical Research and Manufacturers of America (PhRMA) Code, European Federation of Pharmaceutical Industries and Associations (EFPIA) Code

    11. Hyderabad Versus Bangalore Versus Pune for Pharmaceutical, Life Sciences and Semiconductors

    • Talent depth for Pharmaceutical and Life Sciences Research and Development (R&D): Hyderabad is the deepest by a wide margin, Bangalore is the second, Pune is the third.
    • Talent depth for clinical operations, biostatistics and regulatory: Hyderabad is the deepest, Bangalore is the second.
    • Talent depth for biologics and vaccines: Hyderabad is unique. No other Indian city is close.
    • Talent depth for medical devices and Healthcare Information Technology (IT): Bangalore is the deepest, Hyderabad is the second, Pune is a credible third.
    • Talent depth for semiconductors: Bangalore is the deepest, Hyderabad is the second and closing fast, Pune is third for embedded.
    • Cost: Hyderabad is on par with Pune, 18 per cent to 22 per cent cheaper than Bangalore.
    • Attrition: Pune 12 to 16 per cent, Hyderabad 13 to 17 per cent, Bangalore 18 to 24 per cent.
    • Wet laboratory and Biosafety Level 3 (BSL 3) infrastructure: Hyderabad is unique through Genome Valley.
    • Manufacturing adjacency: Hyderabad is unique through Hyderabad Pharma City at Mucherla.
    • Airport connectivity: Hyderabad Rajiv Gandhi International Airport is the best Indian airport for long haul punctuality and cleanliness.

    12. The Anchor Employer Map for Hyderabad Pharmaceutical, Life Sciences and Semiconductor Global Capability Centres (GCCs)

    Hyderabad Pharmaceutical and Life Sciences Global Capability Centres (GCCs) above 1,000 Full-Time Equivalents (FTEs) include Novartis, Sanofi, Bristol Myers Squibb, GlaxoSmithKline (GSK), Pfizer, Bayer, Merck KGaA, Eli Lilly, AstraZeneca, Roche, Takeda, Boehringer Ingelheim, Bayer Crop Science, Syngenta, Biocon Biologics, Bharat Biotech, Dr Reddy's Laboratories, Aurobindo Pharma, Divi's Laboratories, Granules India, Laurus Labs, Suven Life Sciences, Hetero, Indian Immunologicals and Bharat Serums and Vaccines. Hyderabad Semiconductor Global Capability Centres (GCCs) of material scale include Qualcomm, Advanced Micro Devices (AMD), Microsoft Silicon, Intel, Nokia, Cirrus Logic, NXP, MediaTek and Western Digital.

    13. Three Hypothetical Case Vignettes

    13.1 A USD 50 billion European Union (EU) Pharmaceutical parent

    A USD 50 billion European Union (EU) Pharmaceutical parent approves a Hyderabad Pharmaceutical and Life Sciences Global Capability Centre (GCC) expansion from 1,800 to 5,000 Full-Time Equivalents (FTEs) over four years, consolidating discovery chemistry, biologics analytics, clinical data management, biostatistics, regulatory submission writing and Pharmacovigilance from Basel, Cambridge United Kingdom (UK), Boston and Tokyo. The parent uses a HITEC City plus Genome Valley dual anchor. Fully loaded steady state cost in year four, USD 145 million per annum. Equivalent Basel, Cambridge United Kingdom (UK), Boston and Tokyo cost, USD 580 million. Net annual saving, USD 435 million.

    13.2 A USD 1.2 billion United States of America (USA) Biotechnology parent

    A USD 1.2 billion United States of America (USA) Biotechnology parent with no prior India presence approves a Hyderabad Life Sciences Global Capability Centre (GCC) of 280 Full-Time Equivalents (FTEs) over 30 months for biologics discovery, antibody engineering, biostatistics and Pharmacovigilance. The parent elects a Build-Operate-Transfer (BOT) with an Integrated Partner like ChirayuGCC in Genome Valley with a HITEC City satellite. Fully loaded steady state cost in year three, USD 11 million. Equivalent United States of America (USA) cost, USD 42 million. Net annual saving, USD 31 million.

    13.3 A USD 700 million United States of America (USA) Medical Devices parent

    A USD 700 million United States of America (USA) Medical Devices parent approves a Managed Global Capability Centre (GCC) of 140 Full-Time Equivalents (FTEs) in HITEC City to consolidate Software as a Medical Device (SaMD) engineering, Artificial Intelligence (AI) for radiology, regulatory submissions and clinical evidence generation. The Integrated Partner stands up the team in 14 weeks. Fully loaded steady state cost, USD 6.8 million per annum. Equivalent United States of America (USA) cost, USD 26 million. Net annual saving, USD 19 million.

    14. Common Pitfalls and How to Avoid Them

    • Choosing HITEC City for a Research and Development (R&D) charter that needs wet laboratory adjacency. Genome Valley is the right answer, not HITEC City.
    • Hiring the Country Head from a generic Information Technology (IT) Global Capability Centre (GCC) instead of a Pharmaceutical and Life Sciences Global Capability Centre (GCC). Domain depth cannot be retrofitted.
    • Underestimating the time to hire experienced United States of America (USA) Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory writers and biostatisticians. The pool is deep but selective.
    • Skipping the Department of Scientific and Industrial Research (DSIR) Research and Development (R&D) weighted deduction certification under Section 35(2AB) of the Income Tax Act, 1961, which provides material tax benefit.
    • Failing to architect the data estate for the Health Insurance Portability and Accountability Act (HIPAA), the General Data Protection Regulation (GDPR), the Digital Personal Data Protection (DPDP) Act 2023, 21 Code of Federal Regulations (CFR) Part 11 and Computer Software Assurance (CSA) from day one.
    • Treating the semiconductor charter as a subset of the Pharmaceutical charter. They are distinct organisations with distinct leadership, distinct talent and distinct compensation benchmarks.

    15. The 24 Month Outlook for Hyderabad Global Capability Centres (GCCs)

    We expect Hyderabad to add 40 to 55 net new Global Capability Centres (GCCs) and 55,000 to 75,000 net new Full-Time Equivalents (FTEs) through the end of FY 2028. The single largest growth driver will be Pharmaceutical and Life Sciences Research and Development (R&D), clinical operations and regulatory affairs, accelerated by the Generative Artificial Intelligence (AI) productivity uplift in clinical data management, regulatory writing and Pharmacovigilance. The second largest driver will be semiconductor design, accelerated by the India Semiconductor Mission and the Telangana State Semiconductor Policy.

    16. Frequently Asked Questions From Global Chief Executive Officers (CEOs), Chief Scientific Officers (CSOs) and Chief Technology Officers (CTOs)

    • Is Hyderabad deep enough for a 5,000 Full-Time Equivalent (FTE) Pharmaceutical and Life Sciences Global Capability Centre (GCC)? Yes. Multiple existing Hyderabad Pharmaceutical and Life Sciences Global Capability Centres (GCCs) are above 3,000 Full-Time Equivalents (FTEs).
    • HITEC City or Genome Valley? HITEC City for Knowledge Process Outsourcing (KPO) and computational charters. Genome Valley for wet laboratory adjacency. Most mature parents anchor both.
    • What is the realistic cost arbitrage versus New Jersey, Boston, Basel, Cambridge United Kingdom (UK), San Diego or Tel Aviv? 65 per cent to 78 per cent fully loaded.
    • Is Hyderabad credible for semiconductors? Yes, as a second pole after Bangalore and as a primary pole for selected Outsourced Semiconductor Assembly and Test (OSAT) and analog and mixed signal work.
    • What is the realistic time to a productive 300 Full-Time Equivalent (FTE) unit? 11 to 14 months for direct captive, 6 to 8 months for Build-Operate-Transfer (BOT).
    • How does ChirayuGCC differentiate? Integrated Partner model. We are sector specific (Pharmaceutical, Life Sciences, Biotechnology, Medical Devices, Semiconductors) and city specific (Hyderabad with the Genome Valley plus HITEC City plus Pharma City pairing) and operate as your Hyderabad leadership team for the first 24 months.

    17. The Closing Read

    Hyderabad in 2026-2027 is the only Indian city that can credibly host a Tier 1 global Pharmaceutical, Life Sciences, Biotechnology, Medical Devices or Vaccines Global Capability Centre (GCC) at full charter, with wet laboratory adjacency, manufacturing adjacency and a downstream Indian Active Pharmaceutical Ingredient (API), formulation or vaccines manufacturing presence. The talent depth, the Genome Valley cluster, the Hyderabad Pharma City infrastructure, the rising semiconductor cluster and the Telangana State Government's investor friendly stance combine into a structural advantage that will not erode in the next decade. ChirayuGCC, with one hundred plus years of cumulative leadership experience including direct Pharmaceutical sector experience at Torrent and Cipla, is built precisely for this brief. Jai Shri Krishna.

    18. References and Further Reading

    All references below are public, authoritative and non-competitive.

    Originally published 25 June 2026. ChirayuGCC, Your Integrated Partner for Building Global Capability Centres (GCCs) in India. Building Future-Ready GCCs for the World, from Bangalore. Jai Shri Krishna.

    Explore further

    Why BangaloreWhy PuneAll sector hubsSolutionsEngagement modelsROI CalculatorsSuccess storiesAll insights

    Planning a GCC in Hyderabad?

    Share your context and we will respond within one business day with a tailored blueprint. Or call/WhatsApp us right away.

    Call +91 9108246387 WhatsApp us

    Need a deeper conversation? Use the comprehensive enquiry form.

    Related insights

    India
    The Definitive Guide to Setting Up Global Capability Centres (GCCs) in India in 2026-2027, Across Sectors, Verticals and Cities
    Pune, India
    The Definitive Guide to Setting Up Accounting Global Capability Centres (GCCs) in Pune, India in 2026-2027
    Mumbai, India
    The Definitive Guide to Setting Up Banking, Financial Services and Insurance (BFSI) Global Capability Centres (GCCs) in Mumbai, India in 2026-2027
    CallWhatsApp